Stockreport

Beam Therapeutics: Strong Buy On BEAM-101 Progress And In Vivo LNP Shots On Goal [Seeking Alpha]

Beam Therapeutics Inc.  (BEAM) 
PDF BEAM-101 consistently achieved 60% Hemoglobin F induction, December 2025. BEAM-302, an In Vivo LNP candidate for alpha-1 antitrypsin deficiency, exceeded protective A [Read more]